Mycophenolate Mofetil versus Cyclophosphamide in Lupus Nephritis - A Comparison Study with Real-World Data

Filipe Oliveira Pinheiro, Pedro Madureira, Maria Seabra Rato, Lúcia Costa
2022 XXXIX Congresso Brasileiro de Reumatologia   unpublished
BACKGROUND Lupus nephritis is one of the most relevant causes of morbidity and mortality in patients with systemic lupus erythematosus. It is divided into distinct histological classes, and in classes III-V immunosuppressive therapy is indicated, usually with cyclophosphamide (CYC) and mycophenolate mofetil (MMF). The aim of this work is to evaluate the efficacy of CYC and MMF regimens in the treatment of lupus nephritis at our center. METHODS Retrospective longitudinal study that included
more » ... nts diagnosed with lupus nephritis classes III-V. Demographic, laboratory, and clinical data were collected at 0 and 12 months after the diagnosis of lupus nephritis. Comparison between groups (CYC vs MMF) was performed using the chi-square test, t-test, and Mann-Whitney U.
doi:10.47660/cbr.2022.1758 fatcat:6cfdmfwxdzfbnn55eu7yq3tcy4